FDA Narrows Guidance On New Alzheimer's Drug Amid Criticism

FDA Narrows Guidance On New Alzheimer's Drug Amid Criticism

Newsy

Published

Watch VideoThe acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between her agency's drug reviewers and the maker of a controversial new Alzheimer's drug.

Dr. Janet Woodcock announced the extraordinary step via Twitter. It's the latest fallout...

Full Article